BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines help ...
“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in ...
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies This phase I/II, open-label, multicenter study evaluated pivekimab sunirine (PVEK), a novel CD123 ...
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) This phase I/II, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results